Your browser is no longer supported. Please, upgrade your browser.
SYN Synthetic Biologics, Inc. daily Stock Chart
Synthetic Biologics, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own0.13% Shs Outstand19.44M Perf Week-12.01%
Market Cap8.63M Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float19.30M Perf Month-15.68%
Income-15.10M PEG- EPS next Q-0.17 Inst Own7.40% Short Float1.12% Perf Quarter-12.80%
Sales- P/S- EPS this Y75.90% Inst Trans6.56% Short Ratio0.34 Perf Half Y34.49%
Book/sh-0.40 P/B- EPS next Y29.90% ROA-101.90% Target Price- Perf Year-4.31%
Cash/sh0.43 P/C1.07 EPS next 5Y- ROE392.00% 52W Range0.25 - 0.75 Perf YTD-9.84%
Dividend- P/FCF- EPS past 5Y38.60% ROI- 52W High-39.07% Beta2.02
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin- 52W Low81.21% ATR0.05
Employees11 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)40.28 Volatility7.23% 9.59%
OptionableNo Debt/Eq- EPS Q/Q19.90% Profit Margin- Rel Volume0.17 Prev Close0.45
ShortableYes LT Debt/Eq- EarningsAug 06 AMC Payout- Avg Volume627.17K Price0.46
Recom2.00 SMA20-13.46% SMA50-15.70% SMA200-0.18% Volume108,738 Change0.66%
Jan-06-17Reiterated FBR & Co. Outperform $5 → $6
May-06-16Reiterated FBR Capital Outperform $10 → $9
Feb-26-16Initiated FBR Capital Outperform $10
Oct-13-15Initiated RBC Capital Mkts Outperform $8
Mar-16-15Downgrade Maxim Group Buy → Hold $3
Mar-02-15Reiterated Maxim Group Buy $6 → $3
Mar-19-14Reiterated Maxim Group Buy $3 → $6
Sep-30-13Initiated Maxim Group Buy $3
Jun-25-13Initiated Ascendiant Capital Markets Buy $2.25
Jun-30-20 07:00AM  
Jun-15-20 11:41AM  
May-27-20 07:00AM  
May-13-20 12:20PM  
May-06-20 09:55AM  
May-05-20 04:15PM  
Apr-28-20 04:30PM  
Mar-16-20 03:41PM  
Feb-26-20 12:29PM  
Feb-23-20 02:26PM  
Feb-20-20 04:15PM  
Feb-07-20 04:30PM  
Feb-06-20 01:53PM  
Jan-07-20 07:00AM  
Dec-30-19 05:54AM  
Dec-24-19 07:29AM  
Nov-30-19 09:39AM  
Nov-27-19 04:30PM  
Nov-21-19 12:21AM  
Nov-14-19 11:23AM  
Nov-06-19 12:02PM  
Nov-04-19 04:10PM  
Oct-28-19 04:30PM  
Sep-26-19 07:00AM  
Sep-06-19 11:24AM  
Sep-01-19 10:50PM  
Aug-28-19 01:12PM  
Aug-20-19 09:46AM  
Aug-08-19 04:15PM  
Aug-01-19 07:00AM  
Jul-01-19 07:00AM  
May-27-19 03:14PM  
May-24-19 10:25AM  
May-22-19 12:55PM  
May-08-19 06:02PM  
Apr-30-19 04:30PM  
Apr-20-19 03:38AM  
Feb-27-19 04:10PM  
Feb-26-19 10:38AM  
Feb-19-19 04:30PM  
Jan-03-19 07:00AM  
Dec-18-18 10:38AM  
Dec-04-18 12:00PM  
Nov-27-18 08:20AM  
Nov-22-18 09:10AM  
Nov-21-18 09:25AM  
Nov-08-18 06:02PM  
Oct-30-18 04:30PM  
Oct-18-18 08:40AM  
Oct-15-18 01:30PM  
Oct-12-18 07:35AM  
Oct-11-18 09:07AM  
Sep-30-18 09:26AM  
Sep-06-18 07:00AM  
Aug-30-18 04:10PM  
Aug-23-18 09:50PM  
Aug-17-18 02:32PM  
Aug-13-18 07:55AM  
Aug-08-18 05:31PM  
Aug-01-18 05:05PM  
Jul-31-18 07:00AM  
Jun-20-18 07:50AM  
May-22-18 07:00AM  
May-21-18 07:25AM  
May-14-18 11:52AM  
May-09-18 07:48AM  
May-08-18 04:05PM  
Apr-26-18 07:00AM  
Apr-23-18 07:00AM  
Mar-09-18 08:25AM  
Mar-07-18 04:10PM  
Feb-22-18 08:21PM  
Feb-15-18 04:10PM  
Jan-02-18 04:30PM  
Dec-05-17 08:00AM  
Nov-20-17 08:30AM  
Nov-15-17 07:40AM  
Nov-02-17 06:44PM  
Nov-01-17 06:37PM  
Oct-25-17 07:00AM  
Sep-18-17 08:31AM  
Sep-12-17 07:00AM  
Sep-06-17 07:30AM  
Aug-29-17 07:00AM  
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.